Amgen Will Pay|$71 Million to 48 States

(CN) - Amgen will pay $71 million to settle 48 states' complaints that it pushed its blockbuster drugs Aranesp and Enbrel with false claims.

The settlement resolves some issues from a $762 million settlement of criminal and civil claims in 2012 - the largest such fines against a biotech company in history.

Amgen admitted then that it pushed Aranesp, an anemia drug, for off-label uses and at unapproved dosages. Doctors can prescribe drugs for off-label uses, but drug companies are not allowed to push them for it.

Enbrel is used to treat psoriasis, rheumatoid arthritis and other conditions.

Money from the Tuesday settlement will go to 48 states and the District of Columbia.

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Email *

Submit